GLP-1 Drugs May Reduce Migraine Burden

Preliminary study finds GLP-1 medications linked to fewer emergency visits and less need for migraine medications.

Published on Mar. 2, 2026

Got story updates? Submit your updates here. ›

A preliminary study indicates that people with chronic migraine who started taking GLP-1 receptor agonist drugs, such as Ozempic and Wegovy, were less likely to require emergency department visits or hospitalizations compared to those taking traditional preventive medications like topiramate. The observational study suggests these metabolic drugs might help stabilize the 'disease burden' of migraine, potentially through their anti-inflammatory and neurovascular effects.

Why it matters

Chronic migraine can be debilitating, often requiring emergency care and multiple preventive medications. If GLP-1 drugs can help reduce the need for these interventions, it could significantly improve quality of life for those suffering from this neurological condition.

The details

The study matched 11,000 GLP-1 users against 11,000 topiramate users, adjusting for factors like age, BMI, and prior health conditions. It found that GLP-1 users were approximately 10% less likely to visit the emergency department and 14% less likely to be hospitalized over one year. They were also 13% less likely to need triptans (for stopping attacks) and significantly less likely to start new preventive meds like CGRP antibodies (42% reduction) or gepants (23% reduction).

  • The study analyzed data from people who started taking GLP-1 drugs within one year of a chronic migraine diagnosis.

The players

Vitoria Acar, MD

Study author from the University of Sao Paulo in Brazil.

Got photos? Submit your photos here. ›

What they’re saying

“People with chronic migraine often end up in the emergency room or they need to try several preventive medications before finding one that can work for them.”

— Vitoria Acar, MD, Study author (AAN)

“Seeing these patterns of lower use of emergency care and lower use of drugs to stop migraines or trying additional drugs to prevent migraines among people taking GLP-1 drugs for other conditions suggests that these therapies may help stabilize the disease burden in ways that we haven't fully appreciated yet.”

— Vitoria Acar, MD, Study author (AAN)

What’s next

Further clinical trials specifically examining the use of GLP-1 drugs for migraine treatment are needed to determine if there is a direct cause-and-effect relationship.

The takeaway

This preliminary research indicates GLP-1 medications used for diabetes and weight loss may offer an unexpected benefit for chronic migraine sufferers by reducing the need for emergency care and additional migraine medications. If confirmed, this could represent a significant advancement in migraine management.